Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies
Authors' conclusion
Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI.
Study context
- Population
- Patients with active rheumatoid (RA) or psoriatic (PsA) despite treatment (SELECT-COMPARE, SELECT-PsA 1), with attenuation of inflammation (AoI) vs remaining inflammation
- Comparison
- Upadacitinib or adalimumab vs placebo
- Primary endpoint
- Pain (PtGA) in patients with AoI vs remaining inflammation
- Follow-up
- Weeks 12 and 24/26 (PsA/RA)
Methodological detailsphase 3, double-blind, mediation analysis
- Phase 3
- Double-blind
- Mediation analysis
Primary result
As reported in the abstract
RA+AoI: PtGA, least squares mean change from baseline · week 12
Upadacitinib
−42.9
least squares mean change
Adalimumab
−34.7
least squares mean change
Placebo
−33.1
least squares mean change
Upadacitinib vs Adalimumab: P < 0.05 · Upadacitinib vs Placebo: P < 0.05
Further findings
| Outcome | Upadacitinib | Adalimumab | Placebo | P value |
|---|---|---|---|---|
| PsA+AoI: pain improvement · week 12Upadacitinib vs Placebo | −2.7 | −2.8 | −1.8 | P < 0.05 |
| PsA+AoI: pain improvement · week 24Upadacitinib vs Placebo | −3.8 | −3.6 | −2.8 | P < 0.001 |
| PsA: total effects on pain (TJC28 improvement) vs placebo · weeks 16/24Greater than placebo | 2.16 and 2.30 | 1.35 and 1.71 | — not stated in the abstract |
— not stated in the abstract
RA+AoI: PtGA change · week 26
- Improvements were similar across groups by week 26
RA: direct effect on pain (mediation analysis) · weeks 12/26
- Direct effect on pain nearly two times greater with upadacitinib vs placebo compared with adalimumab
Original publication
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies. RMD Open. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →